The genetic landscape of programmed death ligand‐1 (PD‐L1) alterations in head and neck cancer

OBJECTIVES: Nivolumab has recently been shown in the phase III clinical trial CheckMate‐141 to have superior survival rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum‐resistant head and neck squamous cell carcinoma (HNSCC). Nivolumab targets the immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Heineman, Thomas E., Widman, Adam, Kuan, Edward C., St John, Maie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Head and Neck, and Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527359/
https://www.ncbi.nlm.nih.gov/pubmed/28894827
http://dx.doi.org/10.1002/lio2.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527359/
https://www.ncbi.nlm.nih.gov/pubmed/28894827
http://dx.doi.org/10.1002/lio2.79

Ejemplares similares